CONTROVERSIA

This profile has not been translated into English yet. It is shown in French, the reference language (automatic translation tools in your browser can help). Legal statuses and counts are shown in English.

Portrait of Dechra Pharmaceuticals

Portrait: Wikipedia en — See Wikipedia/Wikimedia source page · source

Pharmacie vétérinaire spécialisée

Dechra Pharmaceuticals

Fiche documentée couvrant 10 controverses, dont « Création de Dechra à l’occasion d’un management buy-out » et « Introduction de Dechra à la Bourse de Londres ».

Your opinion of this profile

Profile No. 4390 · Updated on 26 September 2026

10Documented controversies
11Sources
0Formal charge · all time
0Conviction

§ Legal statuses reflect the documented sources as of the date shown; they replace neither court decisions nor the presumption of innocence. Counts are not a rating. Methodology

I. Documented controversies

01

2025-2026

Retraits volontaires de certaines approbations FDA de médicaments vétérinaires

Status not specified

Not yet available in English — French original shown.

La FDA répertorie des retraits volontaires de certaines approbations détenues par Dechra, notamment une approbation de carprofène en 2025 et une de butorphanol en 2026.

Sources · 1

  1. [1]
    U.S. Food and Drug AdministrationVoluntary Withdrawals of Approved New Animal Drug ApplicationsVery high reliability

Last verified: 24 September 2026

02

juin 2025

Cession du portefeuille de vaccins aviaires Avishield à Vaxxinova

Status not specified

Not yet available in English — French original shown.

Dechra annonce la cession de son portefeuille de vaccins aviaires Avishield ainsi que de l’équipe R&D de Zagreb à Vaxxinova.

Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsAvishield AnnouncementVery high reliability

Last verified: 24 September 2026

03

2023-2024

Rachat par EQT et retrait de la cote

Status not specified

Not yet available in English — French original shown.

Le rachat de Dechra par des fonds conseillés par EQT devient effectif en janvier 2024; les actions sont suspendues puis retirées de la cote londonienne.

Attribution
Directly implicated

Sources · 2

  1. [1]
    London Stock Exchange / Dechra PharmaceuticalsScheme of Arrangement Becomes EffectiveHigh reliability
  2. [2]
    Dechra PharmaceuticalsGovernance - Sustainability Report 2024High reliability

Last verified: 24 September 2026

04

2024

Acquisition d’Invetx

Status not specified

Not yet available in English — French original shown.

Dechra acquiert Invetx, société spécialisée dans les biothérapeutiques pour la santé animale, afin d’élargir son pipeline d’innovation.

Legal status — source text
completed
Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsInvetx AcquisitionVery high reliability

Last verified: 24 September 2026

05

2022

Acquisition de Piedmont Animal Health

Status not specified

Not yet available in English — French original shown.

Dechra acquiert Piedmont Animal Health pour environ 210 millions de dollars, renforçant son portefeuille et son pipeline de produits pour animaux de compagnie.

Legal status — source text
completed
Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsAcquisition of Piedmont Animal Health and PlacingVery high reliability

Last verified: 24 September 2026

06

2022

Acquisition de Med-Pharmex

Status not specified

Not yet available in English — French original shown.

Dechra finalise l’acquisition de Med-Pharmex aux États-Unis pour environ 264,5 millions de dollars.

Legal status — source text
completed
Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsDechra Half-Yearly Financial Report for period ended 31 December 2022Very high reliability

Last verified: 24 September 2026

07

2020

Acquisition d’Osurnia auprès d’Elanco après examen de concurrence

Status not specified

Not yet available in English — French original shown.

Dechra acquiert auprès d’Elanco les droits mondiaux sur Osurnia pour environ 135 millions de dollars. L’opération fait l’objet d’un examen de la Competition and Markets Authority britannique, qui la laisse finalement se poursuivre.

Attribution
Directly implicated

Sources · 2

  1. [1]
    UK Competition and Markets AuthorityDechra Pharmaceuticals plc / Osurnia business of Elanco Animal Health merger inquiryVery high reliability
  2. [2]
    Dechra PharmaceuticalsDechra Annual Report 2021Very high reliability

Last verified: 24 September 2026

08

2019

Rappel volontaire de produits ophtalmiques vétérinaires fabriqués par Altaire

Status not specified

Not yet available in English — French original shown.

La FDA publie un rappel volontaire de produits ophtalmiques vétérinaires fabriqués par Altaire Pharmaceuticals et étiquetés exclusivement pour Dechra, en raison de préoccupations sur des contrôles qualité de l’installation du fabricant.

Sources · 1

  1. [1]
    U.S. Food and Drug AdministrationAltaire Pharmaceuticals Issues Voluntary Recall of Veterinary Ophthalmic ProductsVery high reliability

Last verified: 24 September 2026

09

2000

Introduction de Dechra à la Bourse de Londres

Status not specified

Not yet available in English — French original shown.

Dechra est admise à la cote de la London Stock Exchange en 2000.

Legal status — source text
completed
Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsDechra Annual Report 2017Very high reliability

Last verified: 24 September 2026

10

1997

Création de Dechra à l’occasion d’un management buy-out

Status not specified

Not yet available in English — French original shown.

Dechra Pharmaceuticals est constituée en 1997 dans le cadre d’un management buy-out d’activités vétérinaires liées à Lloyds Chemist.

Legal status — source text
completed
Attribution
Directly implicated

Sources · 1

  1. [1]
    Dechra PharmaceuticalsDechra Annual Report 2017Very high reliability

Last verified: 24 September 2026

II. Constellation of documented links

No documented link with another published profile for now.

A documented mention does not, on its own, prove a personal relationship.

III. Your opinion of this profile

One opinion per browser, which you can change at any time. It rates the quality of the profile, not the person.

IV. Has something changed?

A new court decision, a missing source, a mistake? Tell us what should be updated: every request is read by the editorial team.

Update request

Dechra Pharmaceuticals

Say which controversy is concerned and, if possible, give a source. Between 10 and 2,500 characters.

0 / 2500